Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2 ™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population
ConclusionsDYDA 2 is the first randomized, double-blind, placebo-controlled trial to explore the effect of a dipeptidyl peptidase-4 inhibitor on LVSF in T2DM patients in primary prevention regardless of glycemic control. The main characteristics of the enrolled population are reported.Trial registrationClinicalTrial.gov Identifier: NCT02851745.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Heart | Hypertension | Insulin | Obesity | Study